Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
Equillium (Nasdaq: EQ) will host a virtual key opinion leader (KOL) event on November 5, 2025 at 12:00 PM ET to discuss ulcerative colitis (UC) unmet needs and Aryl Hydrocarbon Receptor (AhR) modulation. Experts Francisco J. Quintana, PhD, and Brian Feagan, MD, will review the evolving treatment landscape and the potential of AhR targeting to resolve inflammation and promote mucosal healing.
Company management will present a scientific overview of EQ504, an oral colon‑targeted AhR modulator, summarize preclinical data (IL‑10/IL‑22 signaling, regulatory T‑cell effects, epithelial barrier protection) and outline a Phase 1 proof‑of‑mechanism study expected to initiate mid‑2026. A live Q&A will follow and a replay will be posted in the Investors section of Equillium’s website.
Equillium (Nasdaq: EQ) terrà un evento virtuale con leader di opinione chiave (KOL) il 5 novembre 2025 alle 12:00 ET per discutere delle esigenze non soddisfatte nell'ulcera ulcerativa (UC) e della modulazione del Recettore Arilico AhR. Esperti Francisco J. Quintana, PhD, e Brian Feagan, MD, rivedranno l'evoluzione del panorama terapeutico e il potenziale mirato all'AhR per risolvere l'infiammazione e promuovere la guarigione mucosa.
La direzione dell'azienda presenterà una panoramica scientifica di EQ504, un modulatore AhR mirato al colon da somministrazione orale, riassumerà i dati preclinici (segnalazione IL-10/IL-22, effetti su cellule T regolatrici, protezione della barriera epiteliale) e delineerà uno studio di fase 1 di dimostrazione del meccanismo previsto per l'inizio della metà del 2026. Seguirà una sessione di domande e risposte dal vivo e una riproduzione sarà pubblicata nella sezione Investitori del sito web di Equillium.
Equillium (Nasdaq: EQ) organizará un evento virtual de líderes de opinión clave (KOL) el 5 de noviembre de 2025 a las 12:00 p.m. hora del Este para discutir las necesidades no atendidas de la colitis ulcerosa (UC) y la modulación del receptor aril hidrocarbonado (AhR). Los expertos Francisco J. Quintana, PhD, y Brian Feagan, MD, revisarán el panorama terapéutico en evolución y el potencial de dirigir a AhR para resolver la inflamación y promover la cicatrización de la mucosa.
La dirección de la compañía presentará una visión científica de EQ504, un modulador AhR dirigido al colon y oral, resumirá datos preclínicos (señalización IL-10/IL-22, efectos en células T reguladoras, protección de la barrera epitelial) y esbozará un estudio de fase 1 de demostración del mecanismo previsto para ser iniciado a mediados de 2026. Seguirá una sesión de preguntas y respuestas en vivo y se publicará una repetición en la sección de Inversores del sitio web de Equillium.
Equillium(Nasdaq: EQ)은 2025년 11월 5일 동부 표준시 오후 12:00에 온라인-KOL(주요 의견 리더) 행사를 개최하여 궤양성 대장염(UC) 미충족 수요와 AhR(아릴 탄소 수용체) 조절에 대해 논의합니다. 프란시스코 J. 퀸타나 PhD, 브라이언 피건 MD 등의 전문가들이 진화하는 치료 landscape와 염증 해소 및 점막 치유 촉진을 위한 AhR 표적의 가능성을 검토할 것입니다.
회사는 EQ504의 과학적 개요를 제시하고, 대장 표적 구강용 AhR 조절제에 대해 설명하며, 전임상 데이터(IL-10/IL-22 신호, 규제 T세포 효과, 상피 벽 보호)를 요약하고, 2026년 중반 시작이 예상되는 기전 검증 1상 연구를 개략합니다. 생방송 Q&A 후 Equillium 웹사이트의 투자자 섹션에 재생 영상이 게시될 예정입니다.
Equillium (Nasdaq : EQ) organisera un événement virtuel avec un leader d'opinion clé (KOL) le 5 novembre 2025 à 12h00 ET pour discuter des besoins non satisfaits de la colite ulcéreuse (UC) et de la modulation du récepteur arylhydrocarbure (AhR). Les experts Francisco J. Quintana, PhD, et Brian Feagan, MD, passeront en revue l'évolution du paysage thérapeutique et le potentiel de cibler l'AhR pour résoudre l'inflammation et favoriser la cicatrisation muqueuse.
La direction de la société présentera une vue d'ensemble scientifique de EQ504, un modulateur AhR ciblant le côlon et administré par voie orale, résumera les données précliniques (signalisation IL-10/IL-22, effets sur les cellules T régulatrices, protection de la barrière épithéliale) et exposera une étude de phase 1 de démonstration du mécanisme prévue pour être lancée à la mi-2026. Une séance de questions-réponses en direct suivra et une rediffusion sera publiée dans la section Investisseurs du site web d'Equillium.
Equillium (Nasdaq: EQ) wird am 5. November 2025 um 12:00 Uhr ET eine virtuelle Key Opinion Leader-Veranstaltung (KOL) abhalten, um die unerfüllten Bedürfnisse der colitis ulcerosa (UC) und die Modulation des Arylhydro-Carbonsäure-Rezeptors (AhR) zu diskutieren. Experten Francisco J. Quintana, PhD, und Brian Feagan, MD, werden die sich entwickelnde Behandlungslage und das Potenzial der AhR-Targeting zur Behebung von Entzündungen und zur Förderung der mukosalen Heilung beleuchten.
Das Management des Unternehmens wird einen wissenschaftlichen Überblick über EQ504, einen oral verabreichten kolontargetierten AhR-Modulator, geben, präklinische Daten zusammenfassen (IL-10/IL-22-Signalisierung, Wirkungen regulatorischer T-Zellen, Schutz der Epithelbarriere) und eine Phase-1-Studie zur Demonstration des Mechanismus, die voraussichtlich Mitte 2026 beginnen soll skizzieren. Es folgt eine Live-Q&A-Sitzung, und eine Wiedergabe wird im Investorenbereich der Equillium-Website veröffentlicht.
Equillium (بورصة ناسداك: EQ) ستستضيف حدثاً افتراضياً لروّاد الرأي الرئيسيين (KOL) في 5 نوفمبر 2025 الساعة 12:00 ظهرًا بتوقيت شرق الولايات المتحدة لمناقشة الاحتياجات غير المحققة في داء الأمعاء الالتهابي الخبيث (UC) وتعديل مستقبل الأرلين (AhR). سيستعرض الخبراء فرانسيسكو ج. كوينتانا، دكتوراه في العلوم، وبراين فايغان، دكتور في الطب، مشهد العلاج المتطور والإمكانات لاستهداف AhR لحل الالتهاب وتعزيز شفاء المخاطية.
ستقدم إدارة الشركة لمحة علمية عن EQ504، وهو مُعدِّل AhR فموي يهدف إلى القولون، وستلخص بيانات ما قبل السريرية (إشارات IL-10/IL-22، تأثيرات الخلايا T التنظيمية، حماية الحاجز الظهاري) وتعرض دراسة إثبات الميكانيكية من المرحلة 1 المتوقع انطلاقها في منتصف عام 2026. سيتم عقد جلسة أسئلة وأجوبة مباشرة وستتوفر إعادة للمحادثة في قسم المستثمرين على موقع Equillium الإلكتروني.
Equillium (纳斯达克：EQ) 将在 2025年11月5日东部时间中午12:00 举办一次虚拟关键意见领袖(KOL)活动，讨论弥合溃疡性结肠炎(UC)未满足的需求以及芳香烃受体（AhR）调控。专家 Francisco J. Quintana, PhD, 与 Brian Feagan, MD 将回顾日益发展的治疗格局以及针对 AhR 的潜力，以缓解炎症并促进黏膜愈合。
公司管理层将介绍对 EQ504 的科学概要，这是一种口服、结肠靶向的 AhR 调节剂，概述前临床数据（IL-10/IL-22信号、调节性T细胞效应、上皮屏障保护），并概述一个预计在2026年中启动的 阶段1期机理验证研究。随后将进行现场问答，回放将发布在 Equillium 网站的投资者板块。
- None.
- None.
Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis
LA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced they will host a virtual key opinion leader (KOL) event on Wednesday, November 5, 2025, at 12:00 PM ET.
The event will feature experts in their fields, Francisco J. Quintana, PhD (Harvard Medical School) and Brian Feagan, MD, FRCPC (Western Ontario), who will discuss the unmet needs and evolving treatment landscape in ulcerative colitis (UC) and the promise of targeting AhR to resolve inflammation and promote mucosal healing in this chronic inflammatory disease.
Company management will also provide a scientific and translational overview of EQ504, Equillium’s potent oral, colon-targeted AhR modulator that selectively activates key anti-inflammatory and tissue-regenerative pathways. Presenters will review preclinical data demonstrating EQ504’s differentiated mechanism of action – enhancing IL-10 and IL-22 signaling, driving regulatory T-cell function, and protecting epithelial barrier integrity – and discuss the company’s plans for a Phase 1 proof-of-mechanism study expected to initiate mid-2026.
A live question-and-answer session will follow the formal presentations. To register for the event, please click here. A replay of the webinar will be accessible in the Investors section of Equillium’s website following the event.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.
For more information, visit www.equilliumbio.com.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
FAQ
When is Equillium's ulcerative colitis KOL event for EQ and how do I register?
Who are the presenters at Equillium's November 5, 2025 webinar about EQ504?
What will Equillium say about EQ504 at the November 5, 2025 event?
When does Equillium plan to start the Phase 1 proof‑of‑mechanism study for EQ504 (EQ)?
Will there be an opportunity to ask questions during Equillium's Nov 5, 2025 EQ webinar?
